These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18638094)

  • 1. Effects of parenteral iron on inflammation and the myocardium in hemodialysis patients.
    Sood MM; Oudit GY; Mohammadi H; Huang H; Lok CE
    Hemodial Int; 2008 Jul; 12(3):362-8. PubMed ID: 18638094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
    Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
    Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis.
    Yoshimura K; Nakano H; Yokoyama K; Nakayama M
    Clin Exp Nephrol; 2005 Jun; 9(2):158-63. PubMed ID: 15980952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iron: the iatrogenic kick to lose control over oxygen?
    Deicher R; Hörl WH
    Kidney Blood Press Res; 2002; 25(5):284-8. PubMed ID: 12435873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease.
    Agarwal R; Vasavada N; Sachs NG; Chase S
    Kidney Int; 2004 Jun; 65(6):2279-89. PubMed ID: 15149341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin.
    Weiss G; Meusburger E; Radacher G; Garimorth K; Neyer U; Mayer G
    Kidney Int; 2003 Aug; 64(2):572-8. PubMed ID: 12846752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 16. Pomegranate juice intake attenuates the increase in oxidative stress induced by intravenous iron during hemodialysis.
    Shema-Didi L; Kristal B; Ore L; Shapiro G; Geron R; Sela S
    Nutr Res; 2013 Jun; 33(6):442-6. PubMed ID: 23746559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost savings using a protocol approach to manage anemia in a hemodialysis unit.
    Charlesworth EC; Richardson RM; Battistella M
    Am J Nephrol; 2014; 39(6):509-14. PubMed ID: 24903565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection.
    Kato A; Odamaki M; Nakamura H; Yodoi J; Hishida A
    Kidney Int; 2003 Jun; 63(6):2262-8. PubMed ID: 12753316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
    Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
    J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.